These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22253009)

  • 1. Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents.
    Huang D; Li X; Sun L; Xiu Z; Nishino N
    J Pept Sci; 2012 Apr; 18(4):242-51. PubMed ID: 22253009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: design, synthesis and molecular modeling study.
    Huang D; Li X; Wei Y; Xiu Z
    Eur J Med Chem; 2012 Jun; 52():111-22. PubMed ID: 22465091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
    Jose B; Oniki Y; Kato T; Nishino N; Sumida Y; Yoshida M
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5343-6. PubMed ID: 15454224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222.
    Terracciano S; Di Micco S; Bifulco G; Gallinari P; Riccio R; Bruno I
    Bioorg Med Chem; 2010 May; 18(9):3252-60. PubMed ID: 20381359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
    Wang F; Lu W; Zhang T; Dong J; Gao H; Li P; Wang S; Zhang J
    Bioorg Med Chem; 2013 Nov; 21(22):6973-80. PubMed ID: 24095016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration.
    Wang S; Li X; Wei Y; Xiu Z; Nishino N
    ChemMedChem; 2014 Mar; 9(3):627-37. PubMed ID: 24285590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of mono and bicyclic tetrapeptides thioester as potent inhibitor of histone deacetylases.
    Hoque MA; Islam MS; Islam MN; Kato T; Nishino N; Ito A; Yoshida M
    Amino Acids; 2014 Oct; 46(10):2435-44. PubMed ID: 25048030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
    Zhang Y; Feng J; Liu C; Zhang L; Jiao J; Fang H; Su L; Zhang X; Zhang J; Li M; Wang B; Xu W
    Bioorg Med Chem; 2010 Mar; 18(5):1761-72. PubMed ID: 20171895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.
    Henkes LM; Haus P; Jäger F; Ludwig J; Meyer-Almes FJ
    Bioorg Med Chem; 2012 Jan; 20(2):985-95. PubMed ID: 22182579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.
    Li X; Liu JL; Yang XH; Lu X; Zhao TT; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Jul; 20(14):4430-6. PubMed ID: 22705022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides.
    Nishino N; Shivashimpi GM; Soni PB; Bhuiyan MP; Kato T; Maeda S; Nishino TG; Yoshida M
    Bioorg Med Chem; 2008 Jan; 16(1):437-45. PubMed ID: 17900911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups.
    Park H; Kim S; Kim YE; Lim SJ
    ChemMedChem; 2010 Apr; 5(4):591-7. PubMed ID: 20157916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Search for novel histone deacetylase inhibitors. Part II: design and synthesis of novel isoferulic acid derivatives.
    Lu W; Wang F; Zhang T; Dong J; Gao H; Su P; Shi Y; Zhang J
    Bioorg Med Chem; 2014 May; 22(9):2707-13. PubMed ID: 24702857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
    Nishino N; Yoshikawa D; Watanabe LA; Kato T; Jose B; Komatsu Y; Sumida Y; Yoshida M
    Bioorg Med Chem Lett; 2004 May; 14(10):2427-31. PubMed ID: 15109626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Structure-activity relationships of histone deacetylase inhibitors].
    Tan YM; Huang WY; Yu NF
    Yao Xue Xue Bao; 2009 Oct; 44(10):1072-83. PubMed ID: 20055127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases.
    Bhuiyan MP; Kato T; Okauchi T; Nishino N; Maeda S; Nishino TG; Yoshida M
    Bioorg Med Chem; 2006 May; 14(10):3438-46. PubMed ID: 16439135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.